-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer

PhD Trainee
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, thromboembolism, patient-reported outcomes, Diseases, real-world evidence, thrombotic disorders, Therapies, clinical procedures, Lymphoid Malignancies, Adverse Events, Myeloid Malignancies, Technology and Procedures
Sunday, December 11, 2022: 4:30 PM-6:00 PM
271-273 (Ernest N. Morial Convention Center)
Marc Carrier, MD, MSc, FRCPC, University of Ottawa
Carrier: Servier: Honoraria; Sanofi: Honoraria; Pfizer: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Leo Pharma: Honoraria, Research Funding.
During this special education session, presenters will discuss the ASH guidelines on the prevention and treatment of venous thromboembolism in patients with cancer.

Marc Carrier, MD, MSc, FRCPC

Department of Medicine, University of Ottawa, Ottawa, ON, Canada

Radhika Gangaraju, MD

Institute for Cancer Outcomes and Survivorship, University Of Alabama, Birmingham, AL

Ang Li, MD, MS

Hematology-Oncology, Baylor College of Medicine, Houston, TX